Stellar Biotechnologies Receives US$ 288,000 Payment
Port Hueneme, California - September 30, 2010 (TSX-V: KLH) (US OTC: SBOTF) – Stellar Biotechnologies, Inc. received payment of US$ 288,000 for a filled order of Stellar KLH/SUBUNIT from French biotechnology and active immunotherapy technology-platform company, Neovacs SA (EN Paris: ALNEV.FP), for its Phase IIa human trials with its KLH-based vaccine for rheumatoid arthritis (RA) which has moved to a higher dose group, and its upcoming Phase I trial for Lupus. Neovacs has announced it expects data in second quarter 2011.
Stellar’s customer also announced the RA market for its therapy in 7 major markets is 200,000 patients, and gained consent to proceed to a higher dose in Phase I/II study of their Stellar KLH-based IFN-alpha kinoid in lupus patients.
Darrell Brookstein, Executive VP
All Stellar press releases: http://www.stellarbiotechnologies.com/investors/news_releases/
Stellar Corporate Profile: http://www.stellarbiotechnologies.com/investors/presentation/
Neovacs SA (EN Paris: ALNEV.FP) http://www.neovacs.fr/ is a biotechnology company focused on an active immunotherapy technology platform, holds a broad patent portfolio and is developing therapeutic vaccines for the treatment of AIDS, cancer and auto-immune & allergic diseases. Neovacs is acknowledged as a pioneer in the development of novel therapeutic vaccines against human cytokines (kinoids) and immunosuppressive viral proteins (toxoids). Neovacs' therapeutic vaccines induce a powerful, natural polyclonal antibody response in the patient.
Stellar Biotechnologies, Inc. (TSX-V: KLH) (US OTC: SBOTF) (www.StellarBiotechnologies.com) is a world leader in sustainable manufacturing of pharmaceutical grade immune carrier proteins (ICP), particularly with regard to the present most important pharmaceutical protein in this class, KLH (Keyhole Limpet Hemocyanin). This ancient evolutionary protein has a highly complex structure that makes it ideal for use in human and animal vaccines and diagnostic products. With partners and customers, its flagship Stellar KLH products are in the clinic, and on the way to being established as the only sustainable, long-term pharmaceutical source.
There are forward looking statements in this press release other than purely historical factual information, including statements relating to revenues or profits, or the Company’s future plans. There can be no assurance that such forward-looking statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.